ESMO 2018 | Is RANGE providing the targeted therapies needed for urothelial cancer?
Get great new content delivered to your inboxSign up
Personalized medicine: surgery
Evaluation of costs associated with AEs in urothelial cancer patients
TGF-β/EMT gene signature in low-responders to pembrolizumab
Meaningful, patient-centered research
Rucaparib for urothelial carcinoma: the ATLAS study
More from Thomas Powles